A human antibody that binds to the γ-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo

Thrombosis and Haemostasis

Volumn 82, Issue 3, 1999, Pages 1188-1195

  Refino, Canio J ^a   Himber, Jacques ^b   Burcklen, Louis ^b   Moran, Paul ^a   Peek, Mark ^a   Suggett, Shelley ^a   Devaux, Brigitte ^a   Kirchhofer, Daniel ^a  

^a GENENTECH INC   (United States)

^b Preclinical Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYGLUTAMIC ACID; ANTIBODY; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; ENZYME PRECURSOR; HEPARIN; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BINDING AFFINITY; BLEEDING TIME; BLOOD CLOTTING; CAROTID ARTERY; CAROTID ARTERY FLOW; CONTROLLED STUDY; CUTICLE; DOSE RESPONSE; GUINEA PIG; HEMOSTASIS; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT;

EID: 0032826356     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614351     Document Type: Article

References (45)

1. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and anti-lesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26: 76-82.
2. Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P, Stern D. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991; 88: 1760-65.
3. Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, Rose EA, Schmidt AM. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thoracic Cardiovasc Surgery 1998; 115: 1179-88.
4. Fujikawa K, Legaz ME, Kato H, Davie EW. The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent). Biochemistry 1974; 13: 4508-16.
5. Østerud B, Bouma BN, Griffin JH. Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI. J Biol Chem 1978; 253: 5946-51.
6. Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and Factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
7. Ahmad SS, Walsh PN. Platelet membrane-mediated coagulation protease complex assembly. Trends Cardiovasc Med 1994; 4: 271-7.
8. Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Sem Hematol 1992; 29: 213-26.
9. Toomey JR, Smith KJ, Roberts HR, Stafford DW. The endothelial cell binding determinant of human factor IX resides in the γ-carboxyglutamic acid domain. Biochemistry 1992; 31: 1806-8.
10. Cheung W-F, Hamaguchi N, Smith KJ, Stafford DW. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem 1992; 267: 20529-31.
11. Rawala-Sheikh R, Ahmad SS, Monroe DM, Roberts HR, Walsh PN. Role of γ-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation. Blood 1992; 79: 398-405.
12. Cheung W-F, Van den Born J, Kuhn K, Kjellen L, Hudson BG. Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA 1996; 93: 11068-73.
13. Sugo T, Mizuguchi J, Kamikubo Y, Matsuda M. Anti-human factor IX monoclonal antibodies specific for calcium ion-induced conformations. Thromb Res 1990; 58: 603-14.
14. Liebman HA, Furie BC, Furie B. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa. J Biol Chem 1987; 262: 7605-12.
15. HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44.
16. Sherman-Gold R. Monoclonal antibodies: the evolution from '80s magic bullets to mature, mainstream applications as clinical therapeutics. Genetic engineering news 1997; 17.
17. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnology 1996; 14: 309-14.
18. Suggett S, Refino C, Hass P. Nagel M, Lipari T, Moran K, Judice K, Schroeder H, Lowman C, Adams C, Eaton D, Devaux B, Kirchhofer D. Use of phage display for the generation of human antibodies that neutralize Factor IX function. Blood 1998; 92: 55 (Abstr.)
19. Kelley RF, Refino CJ, O'Connell MP, Modi N, Sehl P, Lowe D, Pater C, Bunting S. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997; 89: 3219-27.
20. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WLT, Rowland AM, Kotts CE, Carver ME, Yang M, Bourell JH, Shepard HM, Henner D. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 1992; 10: 163-7.
21. Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992; 148: 1547-53.
22. Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995; 91: 1568-74.
23. Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997; 78: 1142-9.
24. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
25. Dejana E, Villa S, de Gaetano G. Bleeding time in rats: a comparison of different experimental conditions. Thromh Haemost 1982; 48: 108-11.
26. Sturzebecher J, Kopetzki E, Bode W, Hopfner K-P. Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols. FEBS letters 1997; 412: 295-300.
27. Neuenschwander PF, McCollough J, McCallum CD, Johnson AE. A conformational change in the active site of blood coagulation factor IXa is associated with an increase in activity upon treatment with ethylene glycol. Thromb Haemost 1997; 78 (suppl.): 428 (abstr).
28. Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (Factor VIII:C deficiency) bleeding. Blood 1982; 60: 727-30.
29. Stenflo J, Dahlbäck B. Vitamin-K dependent proteins. In: The molecular basis of blood diseases. 2nd ed. Philadelphia: W. B. Saunders, Company 1994; 565-98.
30. Roux S, Carteaux JP, Hess P, Falivene L, Clozel JP. Experimental carotid thrombosis in the guinea pig. Thromb Haemost 1994; 71: 252-6.
31. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78: 1286-92.
32. Wong AG, Gunn AC, Ku P, Hollenbach SJ, Sinha U. Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arteriovenous thrombosis. Thromb Haemost 1997; 77: 1143-7.
33. Blackburn MN, Feuerstein GZ. Anti-factor IX monoclonal antibody: extended duration of therapeutic protection for arterial thrombosis. Blood 1998; 92 (suppl. 1): 670 (abstr).
34. Ahmad SS, Rawala-Sheikh R, Walsh PN. Platelet receptor occupancy with factor IXa promotes factor X activation. J Biol Chern 1989; 264: 20012-6.
35. Sun Y, Gailani D. Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem 1996; 271: 29023-8.
36. Jones ME, Griffith MJ, Monroe DM, Roberts HR, Lentz BR. Comparison of lipid binding and kinetic properties of normal, variant, and γ-carboxyglutamic acid modified human factor IX and factor IXa. Biochemistry 1985; 24: 8064-9.
37. Larson PJ, Stanfield-Oakley SA, VanDusen WJ, Kasper CK, Smith KJ, Monroe DM, High KA. Structural integrity of the γ-carboxyglutamic acid domain of human blood coagulation factor IXa is required for its binding to cofactor Villa. J Biol Chem 1996; 271: 3869-76.
38. Himber J, Burcklen L, Kelley RF, Kirchhofer D. A soluble tissue factor mutant inhibits thrombus formation in guinea pig carotid arteries. Thromb Haemost 1997; 78: 591-2 (abs).
39. Levine MN, Hirsh J, Salzman EW. Side effects of antithrombotic therapy. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Philadelphia: J. B. Lippencott; 1994; 936-55.
40. Benedict CR, Ryan J, Todd J, Kuwabara K, Tijburg P, Cartwright J, Jr., Stern D. Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model. Blood 1993; 81: 2059-66.
41. Klement P, Liao P, Hirsh J, Johnston M, Weitz J. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. J Lab Clin Med 1998; 132: 181-5.
42. Hovig T, Dodds WJ, Rowsell HC, Mustard JF. The transformation of hemostatic platelet plugs in normal and factor IX deficient dogs. Am J Pathol 1968; 53: 355-74.
43. Sixma JJ, Van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A Brit J Haematol 1984; 58: 741-53.
44. Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995; 91: 1540-4.
45. Smokovitis A, Astrup T. Patterns of activation and inhibition of fibrinolysis in the normal skin of rat, guinea pig and rabbit. J Investigative Dermatology 1978; 70: 321-5.